Good afternoon :)

Thematic MNC Mutual Fund

Thematic funds are the equity mutual funds. They invest in stocks of multinational companies linked to a theme. They are well diversifies and may invest in several sectors around a particular opportunity

  • ⏱ Horizon: Long
  • 🔢 Total funds: 6
  • 💰 Total AUM: 17,333 Cr

Best performing Thematic MNC Mutual Fund

NameAUM (Cr)Exp Ratio (%)1Y Return3Y CAGR5Y CAGR

To view more Thematic MNC Mutual Fund

Visit ScreenerScreener

Overview of Thematic MNC Mutual Fund

ICICI Pru MNC Fund
  • AUM
    ₹ 1,676.89 Cr.
  • Expense Ratio
    1.06%
  • 5Y CAGR
    25.33%
Performance
The fund's annualised performance has been 20.1% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 11.98% vs its category average of 13%.
Composition
Large Cap makes up for the majority of the fund at 46.45% along with the largest allocation towards Pharmaceuticals at 20.73%.
SBI Magnum Global Fund
  • AUM
    ₹ 6,366.36 Cr.
  • Expense Ratio
    1.22%
  • 5Y CAGR
    17.96%
Performance
The fund's annualised performance has been 15.18% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 11.98% vs its category average of 13%.
Composition
Small Cap makes up for the majority of the fund at 40.34% along with the largest allocation towards Pharmaceuticals at 15.37%.
UTI MNC Fund
  • AUM
    ₹ 2,792.68 Cr.
  • Expense Ratio
    1.2%
  • 5Y CAGR
    17.08%
Performance
The fund's annualised performance has been 15.04% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 12.96% vs its category average of 13%.
Composition
Large Cap makes up for the majority of the fund at 42.71% along with the largest allocation towards Pharmaceuticals at 15.57%.
Aditya Birla SL MNC Fund
  • AUM
    ₹ 3,671.76 Cr.
  • Expense Ratio
    1.35%
  • 5Y CAGR
    14.87%
Performance
The fund's annualised performance has been 14.84% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 13.57% vs its category average of 13%.
Composition
Mid Cap makes up for the majority of the fund at 41.24% along with the largest allocation towards Pharmaceuticals at 11.76%.
HDFC MNC Fund
  • AUM
    ₹ 583.93 Cr.
  • Expense Ratio
    1.24%
  • 5Y CAGR
    0%
Performance
The fund's annualised performance has been 13.46% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 13.66% vs its category average of 13%.
Composition
Large Cap makes up for the majority of the fund at 48.24% along with the largest allocation towards Pharmaceuticals at 14.41%.
Kotak MNC Fund
  • AUM
    ₹ 2,241.81 Cr.
  • Expense Ratio
    0.56%
  • 5Y CAGR
    0%
Performance
The fund's annualised performance has been 0% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 13.83% vs its category average of 13%.
Composition
Large Cap makes up for the majority of the fund at 44.58% along with the largest allocation towards Pharmaceuticals at 14.26%.
This compilation has been made as and by way of an update from the publicly available sources of information.This compilation is provided for information purposes only and is not intended to be relied upon by any party as the basis of any decision.

While every effort has been made to take due care in publishing this compilation and to avoid errors or omissions, this compilation is published with a condition and understanding that the Anchorage Technologies Private Limited (ATPL) shall not be responsible for any damages, compensation or loss or action taken or abstained to be taken on the basis of this article/commentary to any person whomsoever.

Investing in Mutual Funds,Stocks/ETFs (Exchange Traded Funds) and securities are subject to market risk. Please read all the related documents carefully before investing. Investors should consider all risk factors and consult their financial advisor before investing. Representations are not indicative of future results.